日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

The efficacy of second-line chemotherapy in the management of classic and iatrogenic Kaposi sarcoma: An analysis of real-world data

二线化疗治疗经典型和医源性卡波西肉瘤的疗效：一项基于真实世界数据的分析

期刊:Medicine
影响因子:1.4
doi:10.1097/MD.0000000000041404
Khanmammadov, Nijat; Ferhatoglu, Ferhat; Paksoy, Nail; Dogan, İzzet; Khishigsuren, Bayarmaa; Nizam, Nihan; Saip, Pinar; Aydiner, Adnan
发表日期：2025
文献求助 收藏

Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer

对复发性卵巢癌患者采用双药化疗方案联合贝伐单抗的疗效进行比较分析

期刊:Medicine
影响因子:1.4
doi:10.1097/MD.0000000000036750
Khanmammadov, Ni Jat; Doğan, İzzet; Okay, Necla Simay; Azizy, Abdulmunir; Saip, Pinar; Aydiner, Adnan
肿瘤
肿瘤免疫
卵巢癌
发表日期：2024
文献求助 收藏

Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients

淋巴结阴性早期乳腺癌患者的长期预后和复发预测因素

期刊:Journal of Cancer Research and Clinical Oncology
影响因子:2.8
doi:10.1007/s00432-023-05276-y
Dogan, Izzet; Aydin, Esra; Khanmammadov, Nijat; Paksoy, Nail; Ferhatoğlu, Ferhat; Ak, Naziye; Emiroglu, Selman; Ibis, Kamuran; Onder, Semen; Tukenmez, Mustafa; Cabioglu, Neslihan; Kucucuk, Seden; Muslumanoğlu, Mahmut; Ozmen, Vahit; Saip, Pinar; Igci, Abdullah; Aydiner, Adnan
肿瘤
肿瘤免疫
乳腺癌
发表日期：2023
文献求助 收藏

Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center

移植后及免疫抑制相关卡波西肉瘤全身化疗的疗效及预后：一家三级癌症中心二十年的经验

期刊:Medicine
影响因子:1.4
doi:10.1097/MD.0000000000035383
Khanmammadov, Nij At; Paksoy, Nail; Doğan, İzzet; Ferhatoğlu, Ferhat; Saip, Pinar; Aydiner, Adnan
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2023
文献求助 收藏

Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study

每周一次紫杉醇治疗经典型卡波西肉瘤一线疗法：一项真实世界研究

期刊:Medicine
影响因子:1.4
doi:10.1097/MD.0000000000032866
Paksoy, Nail; Khanmammadov, Nijat; Doğan, İzzet; Ferhatoğlu, Ferhat; Ahmed, Melin Aydan; Karaman, Sule; Aydiner, Adnan
发表日期：2023
文献求助 收藏

Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

克唑替尼治疗MET基因改变的晚期非小细胞肺癌患者的疗效和安全性：土耳其肿瘤协作组的真实世界数据

期刊:Medicine
影响因子:1.4
doi:10.1097/MD.0000000000032368
Gürbüz, Mustafa; Kiliçkap, Saadettin; Bilici, Ahmet; Karadurmuş, Nuri; Sezer, Ahmet; Şendur, Mehmet Ali Nahit; Paydaş, Semra; Artaç, Mehmet; Fulden Yumuk, Perran; Gürsoy, Pinar; Uysal, Mükremin; Şenol Coşkun, Hasan; Tatli, Ali Murat; Selçukbiricik, Fatih; Dişel, Umut; Köksoy, Elif Berna; Güven, Deniz Can; Uğrakli, Muzaffer; Akkuş, Erman; Yücel, Şebnem; Erol, Cihan; Karakaya, Serdar; Şakalar, Teoman; Khanmammadov, Nijat; Paksoy, Nail; Demirkazik, Ahmet
肺癌
MET
肿瘤
细胞生物学
肿瘤免疫
发表日期：2022
文献求助 收藏